Patent Issued for Engineered immune cell and use thereof (USPTO 11896620).
In: Cancer Gene Therapy Week, 2024-03-07, S. 88-88
serialPeriodical
Zugriff:
A patent has been issued for an engineered immune cell that can be used in cancer immunotherapy. The immune cell expresses a cell surface molecule that recognizes a specific ligand, as well as exogenous interleukin and Flt3L, XCL2, and/or XCL1 genes. The engineered immune cell can be a T cell, macrophage, dendritic cell, monocyte, NK cell, or NKT cell. This technology aims to improve the effectiveness of CAR cell therapy by reducing the inhibitory effect of the tumor microenvironment on CAR cells and recruiting other immune cells to work together with CAR cells. [Extracted from the article]
Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Engineered immune cell and use thereof (USPTO 11896620).
|
---|---|
Zeitschrift: | Cancer Gene Therapy Week, 2024-03-07, S. 88-88 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6837 (print) |
Schlagwort: |
|
Sonstiges: |
|